Folotyn for Non-Hodgkin's Lymphoma Glen Cove NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Michael Schuster
(212) 746-2119
525 East 68th Street
New York, NY
Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
Steven Edward Vogl
(718) 519-7774
2220 Tiemann Ave
Bronx, NY
MARTIN OSTER, MD
(212) 305-8231
161 Fort Washington Avenue
New York, NY
Elisa Jiayi Wu, MD
212-639-7900
650 Commack Rd
Commack, NY
Herbert Gretz
(212) 427-9898
525 E 68Th St
New York, NY
Richard G Stock MD
(212) 241-7502
1184 5th Ave
New York, NY
Norman Lester Rosen
(914) 965-2060
3333 Henry Hudson Way
Bronx, NY
Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
Elisha David Waldman, MD
1275 York Ave
New York, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Glen Cove NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Glen Cove NY